"Intravitreal Bevacizumab With or Without Triamcinolone for Refractory Diabetic Macular..." . "1"^^ . . "We evaluate the effect of intravitreal injections of Bevacizumab (IVB) alone or combined with triamcinolone (IVT) in the first injection for treatment of refractor), diabetic macular oedema (DME). Sixty eyes of sixty patients with refractory DME were included. Half of the receive injections of IVB (1.25 mg/0.05 mL) or combined IVB and IVT (1.25 mg/0.05 mL and 2 mg/0.05 mL respectively). The primary outcome measure was change in central macular thickness (CMT). Secondary outcome measures were change in best-corrected logMAR visual acuity (BCVA) and incidence of potential adverse events. Central macular thickness was reduced significantly in both the IVB and IVB/IVT groups. At week 24, CMT change compared to the baseline was -95.7 mu m (95% CI, -172.2 to -19.26) in the IVB group and -92.1 mu m (95% CI, -154.4 to -29.7) in the IVB/IVT group. There was not a significant difference between the IVB and the IVB/IVT groups (p=0.022)." . . "We evaluate the effect of intravitreal injections of Bevacizumab (IVB) alone or combined with triamcinolone (IVT) in the first injection for treatment of refractor), diabetic macular oedema (DME). Sixty eyes of sixty patients with refractory DME were included. Half of the receive injections of IVB (1.25 mg/0.05 mL) or combined IVB and IVT (1.25 mg/0.05 mL and 2 mg/0.05 mL respectively). The primary outcome measure was change in central macular thickness (CMT). Secondary outcome measures were change in best-corrected logMAR visual acuity (BCVA) and incidence of potential adverse events. Central macular thickness was reduced significantly in both the IVB and IVB/IVT groups. At week 24, CMT change compared to the baseline was -95.7 mu m (95% CI, -172.2 to -19.26) in the IVB group and -92.1 mu m (95% CI, -154.4 to -29.7) in the IVB/IVT group. There was not a significant difference between the IVB and the IVB/IVT groups (p=0.022)."@en . . "Intravitreal Bevacizumab With or Without Triamcinolone for Refractory Diabetic Macular..." . "2"^^ . "Collegium Antropologicum" . "bevacizumab; diabetic macular oedema"@en . "34" . "[FBAEE3241D6D]" . "Vojnikovic, Bozo" . . . "HR - Chorvatsk\u00E1 republika" . "Synek, Svatopluk" . . "264716" . "0350-6134" . . "5"^^ . . . . "I" . "RIV/00216224:14110/10:00061165" . "000283961100021" . "Suppl. 2" . "RIV/00216224:14110/10:00061165!RIV13-MSM-14110___" . "14110" . "Intravitreal Bevacizumab With or Without Triamcinolone for Refractory Diabetic Macular..."@en . . . . "Intravitreal Bevacizumab With or Without Triamcinolone for Refractory Diabetic Macular..."@en .